Le Lézard
Classified in: Health
Subject: FDA

LSNE Receives Approval To Manufacture Commercial Aseptic Generic Product At Its Recently Acquired Facility In León, Spain


BEDFORD, N.H., Sept. 30, 2019 /PRNewswire/ -- Lyophilization Services of New England (LSNE), a privately held contract and development manufacturing organization, announces approval of an Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA), for a sterile injectable product manufactured at their aseptic fill finish facility in León, Spain. The facility acquired in June 2019, is approved for US commercial distribution making it LSNE's fourth facility to gain commercial approval.   

Lyophilization Services of New England (PRNewsFoto/Lyophilization Services of...)

Vice President of Quality and Regulatory, Tom McGrath, stated, "We are thrilled with this ANDA approval. LSNE is dedicated to supporting commercial drug manufacturing opportunities at our newest site and building on our commitment to quality, as evidenced by our successful regulatory history." The LSNE-León site is an integral part of LSNE's overall growth strategy of increasing services, capacity and the footprint of its global network.

About LSNE

LSNE is a privately held company with six GMP facilities ? four located in New Hampshire, one in Wisconsin and one located in León, Spain.  LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology and medical device industries since 1997, specializing in a wide range of services including process development, cGMP fill finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), analytical testing services and regulatory support.  Through the thoughtful integration of six processing facilities, qualified staffing, and an extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a multi-national market.

Media Contact
Jeff Clement
Vice President of Business Development
(603) 668-5763
info@lyophilization.com
www.lyophilization.com

SOURCE Lyophilization Services of New England


These press releases may also interest you

at 04:18
THIS STOCK EXCHANGE RELEASE MAY NOT BE RELEASED, PUBLISHED OR OTHERWISE DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW...

at 04:05
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to...

at 04:00
Merkle (www.merkleinc.com/emea), a leading technology-enabled, data-driven performance marketing agency, released a special edition of its quarterly Customer Engagement Report (CER) focused on the COVID-19 crisis and its impact on marketers. The...

at 03:35
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of...

at 03:30
- The Follow me to be Healthy with Europe campaign has reached its first-year mark, having made more than 32 million impressions on social media; - Funded by Freshfel Europe, Aprifel, and the European Commission, the campaign aims to increase fruit...

at 03:04
Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB (publ)'s ("Calliditas" or the "Company") American Depositary Shares ("ADSs"),...



News published on 30 september 2019 at 13:30 and distributed by: